December 26, 2018 07:52 AM EST
R&D

Lit­tle Capri­cor hits the brakes on a stem cell tri­al for Duchenne MD fol­low­ing an al­ler­gic re­ac­tion

John Carroll

Editor & Founder

The pen­ny stock play­er Capri­cor Ther­a­peu­tics $CAPR has stum­bled in­to an­oth­er pit­fall.

The biotech not­ed that it has vol­un­tar­i­ly halt­ed a clin­i­cal tri­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

New fund will pres­sure flail­ing biotechs, as in­vestor frus­tra­tion boils over

Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

Cari­bou lays off 32% of staff, cuts lu­pus cell ther­a­py pro­gram be­fore first pa­tient

Ab­b­Vie com­mits $10B to ex­pand US foot­print with the threat of tar­iffs ahead

Mer­ck KGaA clos­es in on Spring­Works deal at $3.5B price point

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times